This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KW-2450

Kyowa Hakko Kirin Co., Ltd.

Drug Names(s): KW-2450

Description: KW-2450 was originally developed by Kyowa Hakko Kirin.

KW-2450 is a small molecule insulin-like growth factor receptor (IGF-1R)/insulin receptor (IR) antagonist. It selectively binds to and inhibits the activities of both IGF-1R and IR, possibly resulting in the inhibition of tumour cell proliferation and induction of tumour cell apoptosis.


KW-2450 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug